Independent predictors for mortality in patients with positive Stenotrophomonas maltophilia cultures

Annals of the Academy of Medicine Singapore

Volumn 37, Issue 10, 2008, Pages 826-830

  Kwa, Andrea L H ^a   Low, Jenny G H ^a   Lim, Tze Peng ^a   Leow, Pay Chin ^a   Kurup, Asok ^a   Tam, Vincent H ^b  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b UNIVERSITY OF HOUSTON   (United States)

Author keywords

Outcomes; Predictors; Stenotrophomonas maltophilia

Indexed keywords

PIPERACILLIN PLUS TAZOBACTAM;

ADULT; APACHE; ARTICLE; BACTERIUM CULTURE; FEMALE; GRAM NEGATIVE INFECTION; HOSPITAL INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT ASSESSMENT; PROGNOSIS; RESPIRATORY SYSTEM; RISK FACTOR; STENOTROPHOMONAS MALTOPHILIA;

EID: 56449113874     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Lai CH, Chi CY, Chen HP, Chen TL, Lai CJ, Fung CP, et al. Clinical characteristics and prognostic factors of patients with Stenotrophomonas maltophilia bacteremia. J Microbiol Immunol Infect 2004;37:350-8.
2. Denton M, Kerr KG. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev 1998;11:57-80.
3. Senol E. Stenotrophomonas maltophilia: the significance and role as a nosocomial pathogen. J Hosp Infect 2004;57:1-7.
4. Nicodemo AC, Garcia Paez JI. Antimicrobial therapy of Stenotrophomonas maltophilia infections. Eur J Clin Microbiol Infect Dis 2007;26:229-37.
5. Horan TC, Gaynes RP. Surveillance of nosocomial infections. In: Mayhall CG, editor. Hospital Epidemiology and Infection Control. 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 2004:1659-702.
6. Friedman ND, Korman TM, Fairley CK, Franklin JC, Spelman DW. Bacteraemia due to Stenotrophomonas maltophilia: an analysis of 45 episodes. J Infect 2002;45:47-53.
7. VanCouwenberghe CJ, Farver TB, Cohen SH. Risk factors associated with isolation of Stenotrophomonas (Xanthomonas) maltophilia in clinical specimens. Infect Control Hosp Epidemiol 1997;18:316-21.
8. Muder RR, Harris AP, Muller S, Edmond M, Chow JW, Papadakis K, et al. Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia: a prospective, multicenter study of 91 episodes. Clin Infect Dis 1996;22:508-12.
9. Jang TN, Wang FD, Wang LS, Liu CY, Liu IM. Xanthomonas maltophilia bacteremia: an analysis of 32 cases. J Formos Med Assoc 1992;91:1170-6.
10. Senol E, DesJardin J, Stark PC, Barefoot L, Snydman DR. Attributable mortality of Stenotrophomonas maltophilia bacteremia. Clin Infect Dis 2002;34:1653-6.
11. Labarca JA, Leber AL, Kern VL, Territo MC, Brankovic LE, Bruckner DA, et al. Outbreak of Stenotrophomonas maltophilia bacteremia in allogenic bone marrow transplant patients: role of severe neutropenia and mucositis. Clin Infect Dis 2000;30:195-7.
12. Rispal P, Maugein J, Lasseur C, Marit G, Denisi R, Pellegrin JL, et al. Xanthomonas maltophilia nosocomial infections. A new threat. Apropos of 30 cases (French). Rev Med Interne 1994;15:808-12.
13. Vartivarian SE, Anaissie EJ, Kiwan EN, Papadakis KA. The clinical spectrum of Stenotrophomonas (xanthomonas) maltophilia respiratory infection. Semin Respir Crit Care Med 2000;21:349-55.
14. Kollef MH, Silver P, Murphy DM, Trovillion E. The effect of late-onset ventilator-associated pneumonia in determining patient mortality. Chest 1995;108:1655-62.
15. Penzak SR, Abate BJ. Stenotrophomonas (Xanthomonas) maltophilia: a multidrug-resistant nosocomial pathogen. Pharmacotherapy 1997;17:293-301.
16. Elting LS, Bodey GP. Septicemia due to Xanthomonas species and non-aeruginosa Pseudomonas species: increasing incidence of catheter-related infections. Medicine (Baltimore) 1990;69:296-306.
17. Bjerke HS, Leyerle B, Shabot MM. Impact of ICU infections on outcome from surgical care. Am Surg 1991;57:798-802.
18. Cohn ML, Waites KB. Antimicrobial activities of gatifloxacin against nosocomial isolates of Stenotrophomonas maltophilia measured by MIC and time-kill studies. Antimicrob Agents Chemother 2001;45:2126-8.